Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer.
作者信息
Mao C, Liao R-Y, Chen Q
出版信息
Br J Cancer. 2010 Mar 2;102(5):940. doi: 10.1038/sj.bjc.6605575. Epub 2010 Feb 16.
Abstract
摘要
相似文献
1
Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer.PTEN表达缺失预示着转移性结直肠癌患者对表皮生长因子受体（EGFR）靶向单克隆抗体耐药。
Br J Cancer. 2010 Mar 2;102(5):940. doi: 10.1038/sj.bjc.6605575. Epub 2010 Feb 16.
2
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.多因素分析分子改变预测结直肠癌患者接受 EGFR 靶向单克隆抗体的临床获益。
PLoS One. 2009 Oct 2;4(10):e7287. doi: 10.1371/journal.pone.0007287.
3
KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.KRAS 突变与转移性结直肠癌对抗 EGFR 单克隆抗体的敏感性：一个未解决的问题。
Expert Opin Biol Ther. 2009 May;9(5):565-77. doi: 10.1517/14712590902870394.
4
Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.抗表皮生长因子受体抗体在转移性结直肠癌治疗中的应用
Clin Colorectal Cancer. 2004 Sep;4(3):159-62. doi: 10.1016/s1533-0028(11)70113-x.
5
PTEN status in advanced colorectal cancer treated with cetuximab.西妥昔单抗治疗晚期结直肠癌患者的 PTEN 状态。
Br J Cancer. 2010 Jan 5;102(1):162-4. doi: 10.1038/sj.bjc.6605471. Epub 2009 Dec 1.
6
Anti-epidermal growth factor receptor antibodies in the treatment of metastatic colorectal cancer.抗表皮生长因子受体抗体在转移性结直肠癌治疗中的应用。
Recent Pat Anticancer Drug Discov. 2010 Jun;5(2):142-51. doi: 10.2174/157489210790936270.
7
Panitumumab a novel drug in cancer treatment.帕尼单抗是癌症治疗中的一种新型药物。
Ann Oncol. 2007 Jun;18 Suppl 6:vi16-21. doi: 10.1093/annonc/mdm218.
8
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.PIK3CA 突变/PTEN 表达状态可预测结肠癌细胞对表皮生长因子受体抑制剂西妥昔单抗的反应。
Cancer Res. 2008 Mar 15;68(6):1953-61. doi: 10.1158/0008-5472.CAN-07-5659.
9
Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with p.G13D Mutation.针对具有 p.G13D 突变的转移性结直肠癌的抗 EGFR 单克隆抗体的抗转移活性。
Int J Mol Sci. 2020 Aug 21;21(17):6037. doi: 10.3390/ijms21176037.
10
BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer.BRAF突变预示野生型KRAS转移性结直肠癌对抗表皮生长因子受体单克隆抗体耐药。
J Cancer Res Clin Oncol. 2010 Aug;136(8):1293-4. doi: 10.1007/s00432-010-0922-8. Epub 2010 Jun 1.
引用本文的文献
1
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study.表皮生长因子受体酪氨酸激酶抑制剂联合培美曲塞对比表皮生长因子受体酪氨酸激酶抑制剂单药治疗晚期表皮生长因子受体突变型非小细胞肺癌：一项前瞻性、随机、探索性研究。
Cancer Res Treat. 2023 Jul;55(3):841-850. doi: 10.4143/crt.2022.1438. Epub 2023 Feb 13.
2
Evaluating the value of Amphiregulin, Phosphatase and Tensin Homologue (PTEN) and P21 Expression for Anti-EGFR Treatment in Metastatic Colorectal Carcinoma.评估 Amphiregulin、磷酸酶和张力蛋白同系物（PTEN）和 P21 表达在转移性结直肠癌抗 EGFR 治疗中的价值。
Asian Pac J Cancer Prev. 2021 Apr 1;22(4):1025-1034. doi: 10.31557/APJCP.2021.22.4.1025.
3
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer.分子生物学驱动的转移性结直肠癌治疗
Cancers (Basel). 2020 May 13;12(5):1214. doi: 10.3390/cancers12051214.
4
Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy.伴有 和 野生型转移性结直肠癌患者接受帕尼单抗维持治疗的负性选择。
J Clin Oncol. 2019 Nov 20;37(33):3099-3110. doi: 10.1200/JCO.19.01254. Epub 2019 Sep 20.
5
Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting.瑞戈非尼联合FOLFIRI用于转移性结直肠癌三线或四线治疗的肿瘤学结局
Transl Oncol. 2019 Mar;12(3):502-512. doi: 10.1016/j.tranon.2018.12.003. Epub 2018 Dec 27.
6
Biomarker threshold adaptive designs for survival endpoints.用于生存终点的生物标志物阈值适应性设计。
J Biopharm Stat. 2018;28(6):1038-1054. doi: 10.1080/10543406.2018.1434191. Epub 2018 Feb 13.
7
Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.左侧结肠癌、右侧结肠癌和直肠癌的比较分子分析。
Oncotarget. 2017 Sep 21;8(49):86356-86368. doi: 10.18632/oncotarget.21169. eCollection 2017 Oct 17.
8
EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis.血液中表皮生长因子受体（EGFR）突变检测用于指导非小细胞肺癌患者的EGFR酪氨酸激酶抑制剂治疗：一项系统评价与Meta分析方案
Medicine (Baltimore). 2017 Feb;96(7):e6151. doi: 10.1097/MD.0000000000006151.
9
Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond.非小细胞肺癌中表皮生长因子受体（EGFR）靶向治疗的药物基因组学：EGFR及其他
Chin J Cancer. 2015 Apr 8;34(4):149-60. doi: 10.1186/s40880-015-0007-9.
10
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status.帕尼单抗治疗转移性结直肠癌：肿瘤RAS状态的重要性。
Drugs. 2015 May;75(7):731-48. doi: 10.1007/s40265-015-0386-x.
本文引用的文献
1
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.原发性肿瘤和转移灶中PTEN表达及KRAS突变对转移性结直肠癌患者从西妥昔单抗联合伊立替康治疗中获益的预测作用
J Clin Oncol. 2009 Jun 1;27(16):2622-9. doi: 10.1200/JCO.2008.20.2796. Epub 2009 Apr 27.
2
Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant.原发性结直肠癌及其相关转移部位中表皮生长因子受体（EGFR）和下游蛋白的不同程度失调可能具有临床相关性。
Br J Cancer. 2009 Apr 7;100(7):1087-94. doi: 10.1038/sj.bjc.6604848. Epub 2009 Mar 17.
3
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.结直肠癌中的PIK3CA突变与对表皮生长因子受体（EGFR）靶向单克隆抗体的临床耐药性相关。
Cancer Res. 2009 Mar 1;69(5):1851-7. doi: 10.1158/0008-5472.CAN-08-2466. Epub 2009 Feb 17.
4
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.PTEN表达缺失可预测西妥昔单抗对转移性结直肠癌患者的疗效。
Br J Cancer. 2007 Oct 22;97(8):1139-45. doi: 10.1038/sj.bjc.6604009. Epub 2007 Oct 16.
Zotero 插件